THERAPY DOSSIER · th-fddf7536dd31

CD34 antibody-linked platelets (P-CD34), conjugated via a DSPE-PEG-NHS linker

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30775924 ↗2019Reported benefit

Antibody-Armed Platelets for the Regenerative Targeting of Endogenous Stem Cells.

MixedIschaemia-reperfusionCardiacIntravenous injectionAfter infarction, following three days of intravenous G-CSF pre-treatment given…

Model: Acute myocardial infarction produced by permanent left anterior descending coronary artery ligation, confirmed by triphenyltetrazolium chloride staining

Intravenous P-CD34 accumulated preferentially in the infarcted heart (capture efficiency about 33.6%), increased endogenous CD34-positive cell recruitment, cardiomyocyte proliferation markers and vascular density, preserved viable myocardium and significantly improved ejection fraction and fraction…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…